K L Mahon
Overview
Explore the profile of K L Mahon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
155
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang A, Grogan J, Mahon K, Rasiah K, Sved P, Eisinger D, et al.
Ann Oncol
. 2017 May;
28(8):1903-1909.
PMID: 28486686
Background: Prostate cancers (PCs) with similar characteristics at the time of diagnosis can have very different disease outcomes. Conventional biomarkers of PC still lack precision in identifying individuals at high...
2.
Mahon K, Lin H, Castillo L, Lee B, Lee-Ng M, Chatfield M, et al.
Br J Cancer
. 2015 Apr;
112(8):1340-8.
PMID: 25867259
Background: Docetaxel improves symptoms and survival in metastatic castration-resistant prostate cancer (CRPC). However, ∼50% of patients are chemoresistant. This study examined whether changes in cytokine levels predict for docetaxel resistance...
3.
Mahon K, Qu W, Devaney J, Paul C, Castillo L, Wykes R, et al.
Br J Cancer
. 2014 Aug;
111(9):1802-9.
PMID: 25144624
Background: Glutathione S-transferase 1 (GSTP1) inactivation is associated with CpG island promoter hypermethylation in the majority of prostate cancers (PCs). This study assessed whether the level of circulating methylated GSTP1...
4.
Lin H, Castillo L, Mahon K, Chiam K, Lee B, Nguyen Q, et al.
Br J Cancer
. 2014 Apr;
110(10):2462-71.
PMID: 24714754
Background: Docetaxel is the first-line chemotherapy for castration-resistant prostate cancer (CRPC). However, response rates are ∼50% and determined quite late in the treatment schedule, thus non-responders are subjected to unnecessary...